{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-237704","form_type":"8-K","ticker":"RMD","cik":"0000943819","company_name":"RESMED INC","filed_at":"2021-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:04:21.348094+00:00","generated_at":"2026-06-29T22:14:39.939698+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"ResMed Q4 FY2021 revenue up 14% to $876.1M, dividend increased 8% to $0.42","bullets":["Q4 revenue $876.1M (+14% YoY); non-GAAP operating profit up 7%; diluted non-GAAP EPS $1.35.","Full-year FY2021 revenue $3.2B (+8% YoY); non-GAAP operating profit up 12%; non-GAAP EPS $5.33 (+12%).","Quarterly dividend raised 8% to $0.42/share; payable Sep 23, record Aug 19.","Company cites ongoing recovery in sleep apnea patient flow and tailwind from competitor quality issue.","GAAP net income down 24% for FY due to prior-year gain; non-GAAP net income up 13%."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-237704","json":"https://secwatch.observer/filing/0001193125-21-237704.json","markdown":"https://secwatch.observer/filing/0001193125-21-237704.md","text":"https://secwatch.observer/filing/0001193125-21-237704.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/943819/000119312521237704/0001193125-21-237704-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/943819/000119312521237704/d189129d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T22:14:39.939698+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}